Abstract

LIMA-MARTINEZ, Marcos M. Metreleptin: Treatment for metabolic complications of generalized lipodystrophy. Rev. Venez. Endocrinol. Metab. [online]. 2016, vol.14, n.1, pp.16-28. ISSN 1690-3110.

Metreleptin is a synthetic leptin analog that has been trialed in patients with leptin-deficient conditions. Lipodystrophies represent a class of diseases characterized by leptin deficiency, which is associated with a severe form of the metabolic syndrome characterized by hyperglycemia, hypertriglyceridemia, and hepatic steatosis. These metabolic complications can progress to diabetes mellitus, acute pancreatitis, and hepatic cirrhosis. For the management of these abnormalities, multiple therapies are usually required, and advances stages may be progressively difficult to treat. Metreleptin is the pharmaceutical derived product that has been approved by the US Food and Drug Administration (FDA) to treat the severe metabolic abnormalities of the generalized forms of lipodystrophy. Herein, we review the pharmacological profile of metreleptin, and clinical aspects of generalized lipodystrophies. Further, we examine studies that assessed the efficacy and safety of metreleptin in generalized lipodystrophies.

Keywords : Metreleptin; lipodystrophy; Berardinelli-Seip; leptin.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )